Manhattan Scientifics, Inc.
MHTX · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $1 | $0 |
| Gross Profit | $0 | $0 | $1 | $0 |
| % Margin | – | – | 50% | – |
| R&D Expenses | $2 | $3 | $2 | $3 |
| G&A Expenses | $158 | $189 | $149 | $177 |
| SG&A Expenses | $158 | $189 | $149 | $177 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $160 | $192 | $151 | $180 |
| Operating Income | -$160 | -$192 | -$151 | -$180 |
| % Margin | – | – | -7,550% | – |
| Other Income/Exp. Net | $2 | -$190 | -$103 | -$82 |
| Pre-Tax Income | -$158 | -$382 | -$254 | -$262 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$158 | -$382 | -$254 | -$262 |
| % Margin | – | – | -12,700% | – |
| EPS | -0 | -0.001 | -0.001 | -0.001 |
| % Growth | 57.1% | -40% | 0% | – |
| EPS Diluted | -0 | -0.001 | -0.001 | -0.001 |
| Weighted Avg Shares Out | 559,281 | 559,281 | 559,281 | 559,281 |
| Weighted Avg Shares Out Dil | 559,281 | 559,281 | 559,281 | 559,281 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$2 | $0 | $0 | -$40 |
| EBITDA | -$160 | -$192 | -$254 | -$180 |
| % Margin | – | – | -12,700% | – |